ADHD

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

There was very little evidence of an effect growth or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group.

The potential mediating role of inflammation at 9 years, measured by CRP and IL-6, was investigated in the relationship between sleep and ADHD.

Parenting stress, negative parenting practices, broken parental partnership, critical life events, parental psychopathologies, socioeconomic status, and single-parent family were all significantly associated with ADHD symptom severity.

Some in the industry expect the Adderall shortage to possibly last until March 2023.

Panelists discuss the use of amphetamine XR oral tablets in their practice and for which patients they’re using them.

They also found no statistically significant associations found for specific cardiovascular outcomes in relation to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction.

Data show an enhanced, auditory alert driving simulator may reduce distraction and inconsistent driving among teenagers with ADHD.

The strongest confounders were family income, caregiver education, and ADHD polygenic risk scores for ADHD clinical range diagnoses.

Birgit H. Amann, MD, PLLC, discusses 2 recently approved treatment options for ADHD: amphetamine XR oral tablets and viloxazine.

Panelists discuss the importance of choosing treatments that are individualized to their patients.

Psychiatrists share their approach to choosing between different ADHD medications and formulations.

Dr Feld highlights several formulations that are available to treat ADHD.

Dr Cutler shares treatment options for ADHD.

Dr Amann and other experts discuss importance of carefully weighing patient and parent expectations and goals when choosing treatment.

Drs Cerulli and Cutler discuss factors guiding treatment selection in ADHD.

ADHD experts discuss their approaches to management of ADHD in patients with comorbidities.

The most frequent psychiatric disorder that appeared in patients with ADHD was substance use disorder, followed by mood disorders, anxiety disorders, and personality disorders.

Psychiatrists share how they have incorporated telemedicine in the management of ADHD in their clinics.

Panelists share clinical burden of ADHD and how it impacts pediatric, adolescent and adult populations.

ADHD experts discuss presentation and underdiagnosis of ADHD in adults.

Drs Cerulli, Feld, Cutler, Mao, and Amann discuss prevalence and presentation of ADHD in pediatric, adolescent and adult populations.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

The results also show a bigger increase among adults between 2012-2017, which could be due to increased sensitivity of diagnosis.

Overall, 30.60% of pediatric patients who presented to the emergency department with mild head trauma were diagnosed with ADHD, compared to 8.96% of the control group.

ADHD and ODD dimensions were associated differently with different types of impulsivity, with unique patterns of network connectivity.

The results show pediatric patients with ADHD had a significantly higher risk of injuries requiring hospitalization compared to non-ADHD controls.

Older participants had smaller dual-task performance deficits for gait and texting speed in both the ADHD group and the control group.

Multivariate dimensional association scores resulted in an overall increase and normalization with age in the ADHD.

Prefrontal anodal transcranial direct current stimulation is more effective in treating ADHD compared to stimulation of the right inferior frontal gyrus.